These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 25439987)

  • 1. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
    Bellocq JP; Luporsi E; Barrière J; Bonastre J; Chetritt J; Le Corroller AG; de Crémoux P; Fina F; Gauchez AS; Kassab-Chahmi D; Lamy PJ; Martin PM; Mazouni C; Peyrat JP; Romieu G; Verdoni L; Mazeau-Woynar V
    Ann Pathol; 2014 Oct; 34(5):349-51. PubMed ID: 25439987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
    Luporsi E; Bellocq JP; Barrière J; Bonastre J; Chetritt J; Le Corroller AG; de Cremoux P; Fina F; Gauchez AS; Lamy PJ; Martin PM; Mazouni C; Peyrat JP; Romieu G; Verdoni L; Mazeau-Woynar V; Kassab-Chahmi D;
    Bull Cancer; 2015 Sep; 102(9):719-29. PubMed ID: 26235416
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases.
    Vénat-Bouvet L; Fermeaux V; Leobon S; Saidi N; Monteil J; Mollard J; Aubard Y; Jammet I; Tubiana-Mathieu N
    Anticancer Res; 2014 Mar; 34(3):1213-7. PubMed ID: 24596362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N; Thomssen C
    Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
    Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
    Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
    Jacobs VR; Kates RE; Kantelhardt E; Vetter M; Wuerstlein R; Fischer T; Schmitt M; Jaenicke F; Untch M; Thomssen C; Harbeck N
    Breast Cancer Res Treat; 2013 Apr; 138(3):839-50. PubMed ID: 23568480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
    Schmitt M; Mengele K; Napieralski R; Magdolen V; Reuning U; Gkazepis A; Sweep F; Brünner N; Foekens J; Harbeck N
    Expert Rev Mol Diagn; 2010 Nov; 10(8):1051-67. PubMed ID: 21080821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
    Duffy MJ
    Clin Chem; 2002 Aug; 48(8):1194-7. PubMed ID: 12142372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
    Harms W; Malter W; Krämer S; Drebber U; Drzezga A; Schmidt M
    Anticancer Res; 2014 Aug; 34(8):4457-62. PubMed ID: 25075085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
    Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M
    PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
    Harbeck N; Schmitt M; Kates RE; Kiechle M; Zemzoum I; Jänicke F; Thomssen C
    Clin Breast Cancer; 2002 Aug; 3(3):196-200. PubMed ID: 12196277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
    Look M; van Putten W; Duffy M; Harbeck N; Christensen IJ; Thomssen C; Kates R; Spyratos F; Fernö M; Eppenberger-Castori S; Fred Sweep CG; Ulm K; Peyrat JP; Martin PM; Magdelenat H; Brünner N; Duggan C; Lisboa BW; Bendahl PO; Quillien V; Daver A; Ricolleau G; Meijer-van Gelder M; Manders P; Edward Fiets W; Blankenstein M; Broët P; Romain S; Daxenbichler G; Windbichler G; Cufer T; Borstnar S; Kueng W; Beex L; Klijn J; O'Higgins N; Eppenberger U; Jänicke F; Schmitt M; Foekens J
    Thromb Haemost; 2003 Sep; 90(3):538-48. PubMed ID: 12958624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.